However, in the population treated with a dose-reduction strategy (tPA, 5 mg), end-stage renal disease was not associated with a statistically significant increase in pleural bleeding events (0 of 15 patients [0%] vs 6 of 142 patients [4.2%]; P = .42; OR, 0.96; 95% CI, 0.92-0.99). Here, PLAT is linked to stage 5 chronic kidney disease.